A. H. Partridge

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Giuseppe Viale, O. Pagani, Emiel J. Rutgers, J. Huober et autres

us (code pays fourni par la source)

1817MO Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the breast cancer weight loss (BWEL) trial

JA Ligibel, KV Ballman, LM McCall, P. Goodwin et autres

us, ca (code pays fourni par la source)

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

Zhigang Hu, L.A. Carey, M.G. Soloway, C.M. Perou et autres

PURPOSECALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast cancer. We now …

us (code pays fourni par la source)

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Giuseppe Curigliano, Harold J. Burstein, Michael Gnant, Sibylle Loibl et autres

The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna, Austria, assessed significant new findings for local and systemic therapies for early breast cancer with a focus on the evaluation of multimodal treatment options. The emergence of more …

it, us, at, de, gb, be, ch (code pays fourni par la source)

Abstract PD5-03: Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ in patients with and without index surgery: The effects of endocrine therapy and radiation treatment

Marc D. Ryser, Christel Rushing, Samantha M. Thomas, Thomas Lynch et autres

Abstract Background. Ongoing clinical trials are evaluating active surveillance as a potential alternative to immediate surgery in patients diagnosed with low-risk ductal carcinoma in situ (DCIS). Among women undergoing lumpectomy, the risk of ipsilateral invasive breast cancer (iIBC) after a diagnosis of …

us (code pays fourni par la source)

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)

H. J. Cohen, K. J. Ruddy, C. A. Hudis, Hyman B. Muss et autres

Cyclophosphamide-methotrexate-5-fluorouracil (CMF) is often selected as adjuvant chemotherapy for older patients with early-stage breast cancer due to perceived superior tolerability. We sought to measure persistence with CMF, adherence to oral cyclophosphamide, and the association of these with toxic effects.

Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC)

Antonio Di Meglio, Mayssam El-Mouhebb, Stefan Michiels, Larry R. Jones et autres

fr, us, ca, it (code pays fourni par la source)

Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Giuseppe Curigliano, HJ Burstein, Eric P. Winer, Michael Gnant et autres

Ann Oncol 2017; 28: 1700–1712 (doi: 10.1093/annonc/mdx308) In the original article, panel member H. Khaled’s first and surnames were transposed. This has now been corrected. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the …

Reasons for Rise in CPM Explored

W. Kuznar, I. Jatoi, A. H. Partridge

The rates of contralateral prophylactic mastectomy are increasing in the United States, at the expense of unilateral mastectomy and breast-conserving surgery. Reasons include an overestimation of the risk of developing contralateral breast cancer, anxiety, an increase in the use of genetic testing, …

The electronic self report assessment and intervention for cancer: promoting patient verbal reporting of symptom and quality of life issues in a randomized controlled trial

Donna L. Berry, Fangxin Hong, Barbara Halpenny, A. H. Partridge et autres

BACKGROUND: The electronic self report assessment - cancer (ESRA-C), has been shown to reduce symptom distress during cancer therapy The purpose of this analysis was to evaluate aspects of how the ESRA-C intervention may have resulted in lower symptom distress (SD). METHODS: …

us (code pays fourni par la source)

Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103.

B. P. Schneider, L. Li, Kurt W. Miller, D. Flockhart et autres

1000 Background: Neuropathy, one of the most common toxicities associated with taxane therapy, may be severe, function-limiting, and sometimes irreversible. Established predictors for increased risk include advanced age, diabetes, and type/dose/schedule of taxane. No established biomarkers have been identified to predict patients …

The ASCO Breast Cancer Registry pilot: Implementation of a multisite community practice registry and treatment plan/summary program.

A. H. Partridge, V. W. Norris, Victoria Blinder, Bruce A. Cutter et autres

6101 Background: Current approaches to quality assessment require retrospective data collection that limits opportunities for quality improvement. The goal of the ASCO Breast Cancer Registry (BCR) Pilot was to evaluate the feasibility and acceptability of prospective data collection to support quality assessment …